The M-bcr FusionQuant® Kit is used for the quantitative detection of M-bcr fusion transcripts on real-time thermal cyclers. Ipsogen has designed a very sensitive, reliable and easy to use kit. This real-time PCR kit is intended for the accurate quantification of BCR-ABL p210 transcripts in bone marrow or peripheral blood samples of ALL (Acute Lymphoid Leukemia) or CML (Chronic Myeloid Leukemia) patients previously diagnosed with a M-bcr fusion gene event. The results we obtain are used in monitoring the efficiency of treatment in patients undergoing therapy, and for minimum residual disease (MRD) follow-up to monitor disease relapse.
This finding comes from the CDC's "Fourth National Report on Human Exposure to Environmental Chemicals", which, according to the federal agency, is "the most comprehensive assessment to date of the exposure of the US population to chemicals in our environment".
For the report, CD scientists analyzed blood and urine samples from participants taking part in the CDC's National Health and Nutrition Examination Survey (NHANES), an ongoing survey that every two years samples members of the US population. The Fourth Report includes results from surveys covering 1999 - 2000, 2001 - 2002, and 2003 - 2004.http://www.biocompare.com/Articles/ProductReview/1164/BCL-ABL-M-bcr-FusionQuant-Kits-From-Ipsogen.html